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Effects of the Aminophenol Analogue
p-Dodecylaminophenol on Mouse Skin
Noriko Takahashi1 and Yasunori Fujiu1
p-Dodecylaminophenol (p-DDAP) was designed on the basis of structure–activity relationship studies on N-(4-
hydroxyphenyl)retinamide (fenretinide, 4-HPR), a synthetic derivative of retinoic acid (RA). p-DDAP exhibits
antioxidative activities greater than those of RA and 4-HPR. RA shows biological effects in epidermal cells that
include the inhibition of differentiation to the squamous phenotype. In the current study, we examined the
effects of topical p-DDAP treatment on the skin of hairless mice as compared with those of RA treatment.
p-DDAP caused an increase in epidermal thickness and decreased matrix metalloprotease and hyaluronidase
activities in mouse skin tissues to the same extent that RA did. p-DDAP did not induce desquamation, erythema,
or inflammatory cytokine expression as observed with RA treatment. Two-dimensional polyacrylamide gel
electrophoresis patterns of proteins from skin treated with p-DDAP were distinct from those treated with RA.
A protein induced by both p-DDAP and RA was identified as cytokeratin 16. p-DDAP did not elevate
transcriptional activities of RA nuclear receptors. These results suggest that p-DDAP improves skin as potently
as RA without causing the desquamation and erythema that the latter does. An increase in cytokeratin 16
expression might be essential for the effects of both p-DDAP and RA in skin healing and maintenance.
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INTRODUCTION
Retinoic acid (RA), a carboxylic acid derivative of vitamin
A (retinol), plays many roles in mammalian cells and tissues.
It supports growth in animals, maintains epithelial tissues
and bone, and has a crucial role in spermatogenesis and
reproduction (Kastner et al., 1995). In addition, RA is a
regulator of epidermal proliferation and differentiation, and it
serves as an inhibitor of differentiation to the squamous
phenotype.
The mechanisms for the effects of RA on skin tissue as well
as on other cells have not been fully elucidated. One
mechanism of RA action in development and cell differentia-
tion involves RA nuclear receptors (RARs and retinoid X
receptors) (Kastner et al., 1995; Mangelsdorf and Evans,
1995; Chambon, 1996; Rowe, 1997; Wolf, 2000), which
directly regulate (activate or repress) transcription of their
target genes by binding to specific DNA sequences. Another
mechanism of RA action entails retinoylation (acylation of
proteins by RA) (Takahashi and Breitman, 1989a, b, 1990,
1991, 1994; Takahashi et al., 1991b). We have previously
shown that proteins in undifferentiated and squamous-
differentiated normal human epidermal keratinocytes are
retinoylated in intact cells in vitro (Takahashi et al., 1991a).
Although RA has potent effects on epidermal tissues and
skin tissues, various new retinoids have been synthesized,
because its use can lead to resistance in patients. The retinoid
N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide) is a
synthetic amide of RA. 4-HPR is a potent chemopreventive
and antiproliferative agent that is effective against various
cancers, including skin tumors (Meyskens et al., 1983; Abou-
Issa et al., 1989, 2001; Pienta et al., 1993; Moon et al., 1994;
Takahashi et al., 1995). However, clinical studies of 4-HPR
have also shown side effects, namely, of night blindness and
ocular toxicity.
In view of the above-mentioned resistance and side effects,
we designed a series of p-alkylaminophenols with structures
that are markedly different from those of RA and 4-HPR. Based
on structure–activity relationship studies of 4-HPR, we have
shown that the p-methylaminophenol moiety in 4-HPR
contributes significantly to its anticancer activity as compared
with the 4-aminophenol and p-aminoacetophen moieties
(Takahashi, 2000; Takahashi et al., 2002). Elongation of the
poly-methylene chain in p-methylaminophenol increases
anticancer activity. Among p-aminophenols with various
lengths of alkyl chains, p-dodecylaminophenol (p-DDAP)
was the most potent inhibitor of cell growth when examined
against various cancer cell lines, including human cancer cell
lines that are resistant to RA (Takahashi et al., 2006a).
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Topical administration of retinoid improves the appear-
ance of skin damage arising from photoaging and
chronological aging (Kligman, 1986; Weiss et al., 1988b;
Kligman and Leyden, 1993; Griffiths et al., 1993a; Fisher
et al., 1996; Varani et al., 2000). However, retinoids,
including RA, cause irritation, desquamation, and erythema
on skin and they are teratogenic (Griffiths et al., 1995; Kang
et al., 1995; Regazzi et al., 1997; Basak et al., 2002; Varani
et al., 2007; Hsia et al., 2008). Recently, we found that
p-DDAP shows greater antioxidant activity than RA and
4-HPR (Takahashi et al., 2006a, b; Ohba et al., 2007). These
results led us to examine whether p-DDAP affects epidermal
and skin tissues. In this study, we have shown that p-DDAP
improves the skin of mice as potently as RA without
desquamation and erythema. We also found an increase in
cytokeratin 16 expression induced by both p-DDAP and RA
treatment. This may be significant for skin healing and
maintenance.
RESULTS
Appearance of mouse skin treated with RA or p-DDAP
We investigated whether mouse skins treated topically with
RA or p-DDAP in vivo were distinct from each other. Skin
was treated with vehicle, RA, or p-DDAP daily. In mice
treated with RA for 4 days, desquamation and erythema and
escape behavior were observed (Figure 1a). However, these
symptoms and behaviors were not seen following adminis-
tration of p-DDAP (Figure 1b). p-DDAP did not induce
desquamation by long-term administration (1–2 months).
These results suggest that p-DDAP does not produce the
irritative effects that are associated with RA treatment.
Cytokine gene expression in mouse skin treated with RA or
p-DDAP
As a follow-up to our observation that topical treatment with
RA but not p-DDAP on mouse skin causes desquamation and
erythema, we examined whether cytokine expression levels
in RA-treated skin tissues were different from those in
p-DDAP-treated tissues. After administration of DMSO
(control), RA, or p-DDAP for 4 days, mRNA was extracted
from mouse skin tissues and the mRNA expression of
inflammatory cytokines (IL-1a, IL-1b, IL-6, TNF-a) as well
as MCP-1 was determined using RT-PCR with specific
primers.
With the exception of IL-1a, the expression of cytokines in
the skin tissues was increased significantly by treatment with
RA as compared with control (Figure 2). In particular, RA
markedly elevated the expression of IL-6 (approximately
12-fold) and TNF-a (approximately 5-fold). In contrast, p-
DDAP did not affect the expression of IL-1a, IL-6, TNF-a, or
MCP-1, and it suppressed the expression of IL-1b as
compared with control. These results indicate that the pattern
of inflammatory cytokine expression induced by RA differs
from that by p-DDAP, and that the irritative effects of
desquamation and erythema observed in the skin treated with
RA might be due to an increased expression of cytokines.
Changes in epidermal thickness in mouse skin treated with RA
or p-DDAP
As p-DDAP did not appear to cause irritation to mouse skin,
histological changes were examined and epidermal thickness
was quantitated using tissue specimens that were prepared
from mouse skin treated with RA or p-DDAP and then stained
with hematoxylin and eosin. By quantitative assessment,
RA-treated skin tissues showed an increase in epidermal
thickness (hyperplasia) as compared with control skin (Figure
3a). p-DDAP increased epidermal thickness to the same
extent that RA did (Figure 3b). Thickness after treatment by
both compounds was approximately 1.9-fold greater than
that of control (Figure 3). Epidermal hyperplasia caused by
RA and p-DDAP was due mainly to stratum spinosum
hyperplasia. These results indicate that both p-DDAP and
RA increase epidermal thickness via hyperplasia of the
stratum spinosum.
Changes in ECM metalloproteases (MMPs and HAase) in mouse
skin treated with RA or p-DDAP
p-DDAP did not irritate mouse skin as RA did, but both
p-DDAP and RA, as noted above, increased epidermal
thickness. These results led us to investigate whether
p-DDAP changes the activities of extracellular matrix (ECM)
metalloproteases in mouse skin tissues, including matrix
metalloproteases (MMPs) and hyaluronidase (HAase).
Gelatin zymographies were first performed to measure the
activities of MMPs in RA-treated and p-DDAP-treated mouse
skin tissues. Intensities of bands correlated with the activities
of MMPs. As shown in Figure 4a, bands associated with
MMP-2, proMMP-2, an unknown MMP, and proMMP-9 in
mouse skin tissues treated with RA or p-DDAP decreased as
compared with those from control skin tissues. From the
Control
Control
RA
p-DDAP
Figure 1. Skin irritation in RA-treated and p-DDAP-treated mouse skin.
Mouse skin was treated without (control) or with RA (a) or p-DDAP (b) daily
for 4 days. Changes in mouse skin were observed macroscopically.
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quantitative assessment shown in Figure 4b, MMPs in
RA-treated mouse skin tissues as compared with controls
(100%) decreased approximately 30% for proMMP-9, 36%
for the unknown MMP, 32% for proMMP-2, and 57% for
MMP-2. For p-DDAP-treated skin tissues, proMMP-9, the
unknown MMP, proMMP-2, and MMP-2 were significantly
inhibited to the extent of approximately 77, 40, 50, and 59%,
respectively.
Next, fluorimetric Morgan-Elson assays were performed to
measure HAase activities in RA-treated and p-DDAP-treated
skin tissues. As compared with control (100%), HAase
activities in skin tissues treated with RA or p-DDAP were
reduced by approximately 48 and 40%, respectively
(Figure 5). These results indicate that p-DDAP and RA suppress
the activities of both MMPs and HAase to similar extents.
2D-PAGE patterns of proteins expressed in mouse skin treated
with RA or p-DDAP
The effects of RA and p-DDAP on the skin of hairless mice
include the induction of epidermal hyperplasias and the
inhibition of MMPs and HAase activities. However, skin
irritation was observed only from the administration of RA,
not p-DDAP. These results indicate that p-DDAP promotes
skin healing and maintenance to the same extent as RA
without the latter’s side effects. Therefore, p-DDAP might
be advantageous over RA for skin application. To identify
proteins that may be responsible for the beneficial effects
of RA and p-DDAP, we analyzed protein expression
in mouse skin tissues treated with the two compounds
using two-dimensional polyacrylamide gel electrophoresis
(2D-PAGE). Extracts of skins treated with vehicle, RA, or
p-DDAP were prepared for proteomics analysis. For each
compound, cellular proteins in extracts (150 mg) were
separated by five 2D-PAGEs (pH 3–10, 18 cm; 10%), stained
with SYPRO Ruby, and quantitated by computer image
analysis.
Figure 6 shows a representative gel pattern from among
the five gels. Computer analyses were performed for all
proteins in the five gels. As shown in Figure 6a, 2D-PAGE
patterns of proteins in control and RA-treated skin tissues are
different. Although expression of a protein indicated by an
arrow (protein a) was unchanged in both the presence and
absence of RA treatment, expression of five proteins (proteins
1–5) was increased significantly by RA treatment as compared
with control (Figure 6a, bottom). In contrast, expression of
three proteins (proteins 6, 10, and 11) was increased in
p-DDAP-treated skin tissues, whereas expression of three
proteins (proteins 7, 8, and 9) was decreased significantly as
compared with control (Figure 6b, bottom). The expression
levels of protein a were not different between control and
p-DDAP-treated skin tissues (Figure 6b).
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Figure 2. Expression of cytokines in mouse skin treated with RA and p-DDAP. Mouse skin was treated without (control, a) or with RA (b) or p-DDAP (c)
daily for 4 days. Total RNA (5 mg) was prepared, and reverse transcription PCR was performed using specific primers against each cytokine. After agarose
gel (3%) electrophoresis, PCR products were analyzed by scanning densitometry. The expression levels of cytokine mRNA were normalized to that of
glyceraldehyde-3-phosphate dehydrogenase. The cytokine expression of control was defined as 1.0. Results represent the mean±SD of each group (n¼4).
*Po0.05 versus control compared by Student’s t-test.
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Figure 3. Histological features of RA-treated and p-DDAP-treated mouse
skin. Mouse skin was treated without (control) or with RA (a) or p-DDAP
(b) daily for 2 weeks. At the end of the treatment period, tissues were fixed in
4% buffered formalin and examined using light microscopy after sectioning
and staining with hematoxylin and eosin. Skin epidermal thickness was
assessed quantitatively. Each bar represents the mean±SD (n¼6). *Po0.05
versus control compared by Student’s t-test.
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Proteins1 (Figure 6a) and 6 (Figure 6b) have the same
molecular weight and pI value and were induced by both RA
and p-DDAP treatment. In contrast, the expression of these
proteins was unchanged in control skin tissues. Proteins 1 and
6 increased approximately 1.7-fold and 4.2-fold after treat-
ment with RA and p-DDAP, respectively (Figure 6, bottom).
Treatment with RA also increased the expression of proteins
2–5. p-DDAP increased the expression of proteins 10 and 11
and decreased the expression of three proteins (proteins 7, 8,
and 9). These results indicate that expression of one protein
(protein 1 or protein 6) is increased (induced) by both
compounds.
Identification by 2D-PAGE and MALDI-TOF-MS of proteins
increased by treatment with both RA and p-DDAP
Proteins 1 and 6 induced by both RA and p-DDAP treatment
were analyzed and identified. A section of gel containing
each protein (protein 1 or 6) was excised from a SYPRO
Ruby-stained gel, and peptides were extracted after in-gel
enzyme digestion and then analyzed using matrix-assisted
laser desorption ionization-time of flight mass spectrometry
(MALDI-TOF-MS). The acquired spectra for proteins 1 and 6
showed the same fragmentation patterns (Figure 7a). The
spectra were searched using a Mascot Search engine based
on the entire NCBIn and SwissProt protein database. Both
proteins 1 and 6 were identified as type 1 cytokeratin 16,
which comprises 468 amino acids and has a predicted
molecular weight of 51.842 kDa with a theoretical isoelectric
point of 5.1.
A protein (protein a) unchanged by RA or p-DDAP
treatment was also identified by MALDI-TOF-MS spectro-
metry. The acquired spectra (Figure 7b) were processed and
subjected to database searching. Protein a was identified as
type 1 cytokeratin 10, which comprises 512 amino acids and
has a predicted molecular weight of 52.827 kDa with a
theoretical isoelectric point of 4.9. Identification of cytoker-
atin 16 for proteins 1 and 6 and cytokeratin 10 for protein a
was confirmed by western blot analysis using anti-cytokeratin
16 and anti-cytokeratin 10 antibodies, respectively (data not
shown). These results indicated that cytokeratin 16 was
induced more highly by p-DDAP (4.2-fold) than by RA (1.7-
fold). These results indicate that cytokeratin 16 might be a key
molecule in skin healing and maintenance by RA and
p-DDAP and that p-DDAP could be a more potent inducer
of cytokeratin 16 as compared with RA.
Transcriptional activity of RA, 9-cis-retinoic acid (9-cis RA), and
p-DDAP in CV-1 cells
The results as described above indicated that p-DDAP might
promote skin healing and maintenance to the same extent as
RA without the latter’s side effects. In addition, p-DDAP
induced cytokeratin 16 more potently than RA. Therefore,
the mechanism of action of p-DDAP might be different
from that of RA. To obtain insight into the molecular
mechanisms of p-DDAP action, we investigated whether
p-DDAP activated transcription via RARs (a, b, g) and RXRs
(a, b, g) as compared with their ligands, RA and 9-cis-RA,
respectively.
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Figure 4. Gelatin zymography of MMPs in RA- and p-DDAP-treated mouse
skin. Protein extracts (4 mg) prepared from mouse skin treated without
(control) or with RA or p-DDAP were applied to gelatin-impregnated gels.
After electrophoresis, gels were incubated for 16 hours at 37 1C in 50mM
Tris-HCl (pH 7.6) containing 5mM CaCl2, 0.2M NaCl, and 1mM ZnCl2.
(a) Typical gelatin zymographic patterns were observed. (b) MMPs bands
were densitometrically quantified by computer image analysis. The intensities
of control bands were defined as 100%. Each bar represents the mean±SD
(n¼6). *Po0.05 versus control compared by Student’s t-test.
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Figure 5. Comparison of HAase activities in mouse skin treated with RA or
p-DDAP. HAase activities were measured in mouse skin treated without
(control) or with RA (a) or p-DDAP (b). One unit of HAase activity was
defined as the amount of enzyme required to produce 1 mmol of reducing
terminal GlcNAc per minute under the specified conditions. Each bar
represents the mean±SD (n¼ 6). *Po0.05 versus control compared by
Student’s t-test.
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As shown in Figure 8, RA (b, 0.1 mM; c, 1 mM) and 9-cis RA
(g, 1 mM) exhibit significant transactivation activities mediated
by RARs (a, b, g) and RXRs (a, b, g), respectively. In contrast,
p-DDAP at concentrations of 0.5 mM (d), 1 mM (e), and 1 mM (f)
did not activate transcription via RARa, RARb, RARg, RXRa,
RXRb, and RXRg. The levels of transactivation against these
receptors were the same as control (a) and were dose-
independent (Figure 8). These results indicate that p-DDAP
may exert its effects without binding to RARs (a, b, g) and
RXRs (a, b, g) and activating transcription of their target
genes.
DISCUSSION
The focus of the current study was on examining the effects of
topical treatment with p-DDAP on mouse skin as compared
with RA. It was found that p-DDAP increased epidermal
thickness (hyperplasia) and suppressed ECM metallopro-
teases, including MMPs and HAase, to an extent similar to
that with RA (Figure 3–5). Desquamation, erythema, and
inflammatory cytokine expression caused by RA administra-
tion were not observed following p-DDAP treatment (Figures
1 and 2). Treatment with p-DDAP or RA altered protein
expression, with cytokeratin 16 being induced by treatment
with both compounds (Figure 6–7). RA nuclear receptors
were not involved in the action of p-DDAP (Figure 8). These
results indicate that p-DDAP could potentially be superior to
RA for skin treatment and maintenance.
Topical administration of retinoids, including RA, impro-
ves the appearance of skin damage due to photoaging and
chronological aging of skin tissues, including freckles and
wrinkles (Kligman, 1986; Weiss et al., 1988a, b; Kligman and
Leyden, 1993). However, RA can potentially show side
effects of irritation and teratogenicity. In damaged skin, there
is an increase in fragmented collagen and a loss of intact
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Figure 6. Comparison of 2D-PAGE patterns of proteins in RA-treated and p-DDAP-treated mouse skin. Proteins (150mg) prepared from mouse skin
treated without (control) or with RA (a) or p-DDAP (b) were separated by 2D-PAGE with Immobiline DryStrip (pH 4–7, 18 cm) and 10% 1D-PAGE and stained
using SYPRO Ruby. Gel patterns shown are representative of five gels in each condition. Intensities of protein spots were analyzed by computer image
analysis. Each bar represents the mean±SD. *Po0.05 versus control compared by Student’s t-test.
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collagen. RA treatment reverses the increased expression of
ECM metalloproteinases that are responsible for collagen
degradation in the skin tissues (Fisher et al., 1996) while
stimulating collagen synthesis (Griffiths et al., 1993b; Varani
et al., 2000). However, retinoids and RA can cause skin
irritation and inflammation (Griffiths et al., 1995; Kang et al.,
1995; Basak et al., 2002).
Epidermal hyperplasia may result from enhancement of
cytokeratin expression, accompanied by the elevation of the
turnover rate. This may induce rapid excretion of melanin in
keratinocytes with the appearance of freckles (Ortonne,
2006). In photoaging and chronological aging of skin tissues,
the activities of MMPs and HAase that degrade ECM (e.g.,
collagen, elastin, hyaluronic acid) are increased. Conse-
quently, the decrease in ECM induces wrinkles (Lateef et al.,
2004; Chung and Eun, 2007). In this study, we showed that
p-DDAP suppresses the expression of ECM metalloprotei-
nases without skin irritation (Figures 1–5). p-DDAP might
suppress the differentiation of keratinocyte into a cornified
layer, as the spinous cell layer is increased in thickness in
hyperplastic skin treated with p-DDAP. As a result, p-DDAP
may improve wrinkles and freckles by inhibiting differentia-
tion of keratinocytes. It would be interesting to investigate
whether skin freckles and wrinkles are eliminated by
treatment with p-DDAP.
To elucidate potential mechanisms behind the actions of
p-DDAP, we examined changes in protein expression in skin
tissues after p-DDAP treatment as compared with RA.
Although the patterns of protein expression in p-DDAP and
RA treatment were distinct, the expression of cytokeratin 16
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was induced in both cases (Figures 6–7). The roles of
cytokeratin 16 are not well known. In addition, the actions
of p-DDAP were not mediated by RA nuclear receptors
(Figure 8). Given that cytokeratin 16 is a promoter of
cytokeratin formation, p-DDAP might serve as an accelerat-
ing agent on cell growth, leading to hyperplasia.
The expression of type I (K9–K23) and type II (K1–K8)
keratins is strictly regulated in a specific manner in
keratinocyte proliferation/differentiation. In normal epider-
mis, K1 and K14 are expressed in the basal layer and K1 and
K10 in the suprabasal layer. K16 is not detectable in the
epidermis, but can be induced in stratified epithelia during
hyperproliferation and aberrant differentiation, for example,
psoriasis, cancer, or ultraviolet exposure (Barker et al., 1993;
Paramio et al., 1999; Sano et al., 2009). Thus, K16 expression
is modified during cell proliferation (Paramio et al., 1999)
and hyperproliferation-associated differentiation (van Rossum
et al., 2000; Wawersik and Coulombe, 2000). However, the
relationship between K16 expression and cell proliferation/
differentiation is extremely complicated and not understood.
In contrast, RA inhibits differentiation to the squamous
phenotype and induces keratinocyte formation and K16
expression. In the current study, p-DDAP induced keratino-
cyte formation and K16 expression and inhibited ECM
metalloproteinase activities as potently as RA (Figures 3–7).
In addition, previous studies have shown that p-DDAP is an
excellent antioxidant, having approximately 300-fold higher
potency than RA (Takahashi et al., 2006b). Further studies are
required to elucidate whether p-DDAP inhibits differentiation
similarly to RA and whether K16 expression and the
antioxidant activity by p-DDAP are significant for the
inhibition of ECM metalloproteinase activities and for
differentiation.
Treatment with RA can potentially result in irritation and
inflammation. These are due to the structure of RA, which
includes a hydrophilic carboxyl residue and a hydrophobic
long-chain hydrocarbon having a conjugated double bond.
Such a structure is similar to that of detergents (surface-active
agents) (Meeks et al., 1981). In this respect, p-DDAP
possesses the same length carbon chain without the
double bond. The phenol residue serves as a hydrophilic
residue. Accordingly, p-DDAP is less similar to a detergent
than RA. In our study, RA induced irritation and expression of
several cytokines; however, this was not the case with
p-DDAP (Figures 1 and 2). The fact that p-DDAP causes less
irritation than RA might be attributable to a reduction in
detergent characteristics and reduced cytokine-expression
induction.
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Figure 8. Transcriptional activity of RA, 9-cis RA, and p-DDAP. Cells were transfected with expression plasmids for RARa, RARb, RARg, RXRa, RXRb, or RXRg,
the luciferase reporter plasmid, and the control Renilla luciferase expression plasmid. Cells were treated with RA, 9-cis RA, and p-DDAP, and luciferase
activities were measured. The activities of 1 mM RA or 1 mM 9-cis RA were defined as 100%. Each bar represents the mean±SE (n¼3). a: DMSO, b: 0.1 mM RA,
c: 1mM RA, d: 0.5 mM p-DDAP, e: 1 mM p-DDAP, f: 2mM p-DDAP, g: 1mM 9-cis RA.
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In this study, we found that p-DDAP showed improved
protective effects on skin without adverse effects. Cytokeratin
16 might be a key molecule in the action of p-DDAP on skin.
Treatment with p-DDAP influences various physiological
processes in skin tissues, including enhancement of cell
communication and inhibition of metabolic activation.
MATERIALS AND METHODS
Chemicals
RA, 9-cis RA, ethylenediaminetetraacetic acid, bovine serum
albumin (BSA, fraction V) and DMSO were obtained from Sigma
Chemical (St Louis, MO). p-DDAP was synthesized as described
previously (Takahashi et al., 2003a, 2006a, b).
Animals
Specific pathogen-free hairless mice (HR-1, 8 weeks of age, male)
were purchased from Sankyo Labo Service (Tokyo, Japan). To generate
compound-treated mice, compounds at a concentration of 0.1% in
DMSO (20ml, 2 cm2) or (10ml cm2) were administered topically to
dorsal skin. Mice were divided into three experimental groups (n¼ 6)
that were treated with DMSO (control), p-DDAP, or RA as described
previously (Rosenthal et al., 1990; Warner et al., 2008). The
compounds were administered daily for either 1 or 2 weeks. Animal
experiments were conducted with the ethical approval of the Hoshi
University Institutional Animal Care and Use Committee.
Skin specimens
Hairless mouse skin specimens were incubated in 4% paraformal-
dehyde solution at 4 1C for 16 hours. After fixation, the solutions
were replaced sequentially with 10, 20, and 30% sucrose in
phosphate-buffered saline (PBS). The specimens were embedded
with OCT compound (Sakura, Finetek Japan, Tokyo, Japan) and
subjected to histological evaluation. Embedded skin tissues were
frozen in dry ice/isopentane and then sliced at 4 mm thickness using
a cryostat (CM1850, Leuca Microsystems CML, Germany). Resultant
sections were placed on aminopropylsilane-coated slides (Matsuna-
mi Glass Ind., Osaka, Japan), dried, and stained with hematoxylin
and eosin. Skin epidermal thickness was assessed quantitatively
(Rosenthal et al., 1990; Warner et al., 2008).
RT-PCR
Total RNA was prepared from mouse skin tissues treated with and
without compounds using ISOGEN (Nippon Gene, Tokyo, Japan)
according to the manufacturer’s instructions. For RT analysis, 5 mg of
RNA were reverse-transcribed using the Superscript VILO cDNA
synthesis kit (Invitrogen, San Diego, CA) according to the manu-
facturer’s instructions. The RT reactions were then amplified with
specific primers for cytokines (IL-1a: sense 50-TCTTTTTCCCTCCCA
TCCTT-30, antisense 50-AATTGGAATCCAGGGGAAAC-30; IL-1b:
sense 50-AGTTGGACAACAAACCCTGC-30, antisense 50-AAGCCCA
AAGTCATCAGTG-30; IL-6: sense 50-TGCTGGTGACAACCACGGC
C-30, antisense 50-GTACTCCAGAAGACCAGAGG-30; TNFa: sense
50-CCTGTAGCCCACGTCGTAGG-30, antisense 50-TTGACCTCAGC
GCTGAGTT-30; MCP-1: sense 50-ACCAGCAAGATGATCCCAAT-30,
antisense 50-TGTCTGGACCCATTCCTTCT-30) and glyceraldehyde-
3-phosphate dehydrogenase . The PCR products were separated by
electrophoresis in 3% agarose gel and visualized.
Preparation of skin extract for assay of ECM metalloproteinase
Skin tissues (0.1 g, wet weight) from each animal were cut into
pieces and suspended in 1ml of 0.05M Tris-HCl buffer (pH 7.5)
containing 0.2M NaCl, 5mM CaCl2 and 0.1% Triton X-100 and then
homogenized by a polytoron homogenizer (ULTRA-TURAX T8, IKA-
WERKE GmbH, Stanfen, Germany) on ice for 40 seconds (three
times). Skin homogenates were centrifuged (10,000g, 30min), and
the resultant supernatants were assayed for ECM metalloproteases,
including MMPs and HAase. Protein content was measured using the
Bicinchoninic Acid Protein Assay (Pierce, Rockford, IL).
Gelatin zymography assay for MMP activity
Skin extract proteins (1.5 mg) were applied to gelatin-impregnated gel
(8% polyacrylamide gel containing 1mgml–1 gelatin) according to
the procedure of Lateef et al. (2004). After electrophoresis, gels were
incubated for enzyme reactions in 50mM Tris-HCl (pH 7.5)
containing 5mM CaCl2, 0.2M NaCl and 1mM ZnCl2 for 16 hours
at 37 1C. After incubation, gels were stained with Coomassie brilliant
blue R-250 (CBB, Sigma) and destained. MMP activity was
quantitated in clear bands using Chemi Stage CC-16H (KURABO
Ind., Osaka, Japan).
Assay for HAase activity
HAase activity was determined by the Morgan-Elson fluorimetric
assay (Takahashi et al., 2003b). Briefly, 120ml of substrate solution
(1.5mgml–1 hyaluronic acid in 0.1 M formate buffer, pH 3.5,
containing 0.1 M NaCl and 1.5mM saccharic acid 1,4-lactone) was
mixed with 10 ml of skin extract (10 mg) and 1.0mgml–1
N-acetylglucosamine (GlcNAc). The reaction mixture was incubated
at 37 1C for 18 hours and heated in a bath of boiling water for
5minutes to terminate the enzyme reaction. After the mixture had
cooled to room temperature, the Morgan-Elson reaction was
performed. p-Dimethylaminobenzaldehyde reagent (0.07M,
0.75ml) was added into the supernatant and incubated at 37 1C for
20minutes. After centrifugation at 18,000g at 4 1C for 10minutes to
remove turbidity, the newly released reducing-terminal GlcNAc in
the clear supernatant was detected by fluorescence (excitation,
545 nm; emission, 604 nm) with a Hitachi F-4500 fluorescence
spectrophotometer (Hitachi, Tokyo, Japan). One unit of HAase
activity was defined as the amount of enzyme required to produce
1mmol of reducing-terminal GlcNAc per minute under the specified
conditions. Standard curves were plotted from known concentra-
tions of GlcNAc.
Preparation of skin extract for proteomics
Skin tissues (0.1 g, wet weight) from each animal were sectioned,
suspended in 0.5ml of protein-solubilizing solution (9.5M urea, 2%
NP-40, and 1/100 volume protease inhibitor cocktail), and homo-
genized using a polytoron homogenizer (ULTRA-TURAX T8) on ice for
40 seconds (three times). Skin homogenates were centrifuged
(10,000g, 30minutes). Resultant supernatants were concentrated by
centrifugation (5,000g, 40minutes) using Ultrafree-MC (Millipore,
Bedford, MA). Proteins were measured using the procedure of Bradford
(1976) with BSA as a standard (Bio-Rad Laboratories, Hercules, CA).
One-dimensional polyacrylamide gel electrophoresis
One-dimensional polyacrylamide gel electrophoresis (1D-PAGE)
was performed according to Laemmli’s method (Laemmli,
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1970). Briefly, sample solutions containing 10mg of skin extract were
heated, and then electrophoresis on 10% polyacrylamide gels
(1.0mm thick) was performed for proteomics analysis. Prestained
protein molecular-weight markers were obtained from GIBCO BRL
(Grand Island, NY).
Two-dimensional polyacrylamide gel electrophoresis
2D-PAGE was performed according to the procedure of O’Farrell
(1975). First, isoelectric focusing gels (Immobiline DryStrip, pH 4–7,
7 or 18 cm, General Electric, UK) were run along one axis with skin
extract (150, 200, and 300 mg). Next, 10% polyacrylamide gels were
run along the second axis. Gels were fixed and stained with CBB
(Sigma) or SYPRO Ruby gel stain (SYPRO Ruby, Invitrogen).
Prestained protein molecular weight markers were obtained from
GIBCO BRL.
Immunostaining
Proteins were separated by 1D- and 2D-PAGE and transferred to
a polyvinylidene difluoride (PVDF, Millipore) membrane using an
electroblotter (Bio Craft, Tokyo, Japan). Antigen reactivity with
primary antibodies was visualized by chemiluminescence staining
using a western blotting starter kit (ECL plus, General Electric)
according to the manufacturer’s instructions. Gels were fixed,
stained with CBB (Sigma), analyzed, and quantitated by computer
image analysis in Typhoon 9400 (General Electric).
MALDI-TOF-MS
Matrix-assisted laser desorption ionization–time of flight mass
spectrometry (MALDI-TOF-MS) was performed according to the
manufacturer’s instructions (O’Farrell, 1975; Katayama et al.,
2004). CBB-stained spots were excised from the 2D-PAGE gels
and transferred to microcentrifuge tubes. The spots were destained
with a solution containing 50% acetonitrile and 25mM NH4HCO3
and then dried by a vacuum centrifuge (Speed Vac, Savant,
Farmingdale, NY). The gels were first incubated in a reducing
solution (10mM dithiothreitol, 25mM NH4HCO3) at 56 1C for
1 hour on a shaker and then in a washing solution (25mM
NH4HCO3) at room temperature for 10minutes. Gels were
incubated in an alkyl solution (55mM ICH2CONH2) at room
temperature for 45minutes on a shaker in the dark and then in a
washing solution (25mM NH4HCO3) at room temperature for
10minutes. Gels were dehydrated with a solution containing 50%
acetonitrile and 25mM NH4HCO3 at room temperature for
10minutes and dried on a Speed Vac. Gels in trypsin solution
(10 mgml–1) containing 10mM NH4HCO3 were placed on ice for
30minutes and incubated at 37 1C overnight. The gels were vortexed
vigorously for 30minutes with an extraction solution (50%
acetonitrile and 5% CF3COOH). The digested solutions were
transferred into tubes and dried by Speed Vac. The resultant pellets
were dissolved in 0.1–0.5% trifluoroacetic acid. The solutions were
then desalted using Zip Tips (Millipore) and dissolved in a matrix
solution containing a-cyano-4-hydroxycinnamic acid (5mgml–1) in
50% acetonitrile and 0.1% trifluoroacetic acid, and subjected to
MALDI-TOF-MS analysis (Shimadzu, Kyoto, Japan). Mass spectral
fragment fingerprints were analyzed using the software PEAKS Studio
(Infocom, Tokyo, Japan). The MASCOT database was searched to
identify proteins.
Transfection and luciferase reporter gene assay
CV-1 cells were transfected with reporter and expression constructs
(Suhara et al., 2009). Briefly, CV-1 cells were seeded at 2 105 per
well in six-well culture dishes and after overnight culture transiently
transfected with 1 mg each of pGal4DBD/NR-LBD expression
plasmid and 0.9 mg of pG5-Luc luciferase reporter plasmid, together
with 0.1 mg of the control Renilla luciferase expression plasmid
pGL4.75hRluc-CMV per well using FuGENE HD (Roche Diagnos-
tics, Indianapolis, IN) as a transfection reagent. Cells were harvested
6 hours after transfection, washed once with PBS, and plated again at
1.6 104 per well in 96-well plates. p-DDAP, positive controls, or
their dilutions were added to the culture and the cells were
incubated at 37 1C for 48 hours. Dilution of p-DDAP and positive
controls was performed with DMSO. After being washed with PBS,
cells were lysed with passive lysis buffer and the lysates were used
for the reporter assay. The reporter expression was evaluated by
measuring the activity of firefly luciferase using the dual luciferase
reporter assay system (Promega) and ARVO HTS 1420 multilabel
counter (PerkinElmer, Waltham, MA) as a luminometer according to
the manufacturer’s instructions. Firefly luciferase activity was
corrected for transfection efficiency based on the activity of the
internal control, Renilla luciferase.
Statistical analysis and presentation of results
The statistical significance of the data was evaluated using Student’s
t-test. Po0.05, Po0.01, and Po0.001 were considered significant.
Each experiment was performed at least four times, and most
experiments were repeated at least three times with consistent results.
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